Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

Summary

The purpose of the study is to assess the efficacy and safety and PK of AZD8931 plus paclitaxel versus paclitaxel alone in patients with metastatic, gastric or gastro-oesophageal junction, cancer.

Timeline

Start

2012-04

Primary completion

2013-03

Completion

2013-03

Outcome

Missed primary endpoint

Stopped: “AstraZeneca sponsored trials of AZD8931 have been halted”

registry analysis (superiority or other test); AZD8931 + Paclitaxel vs Placebo + Paclitaxel; p = 0.688 NCT01579578 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SAPITINIB	Small molecule	40 mg	Oral
Background	Paclitaxel	Small molecule	—	Intravenous

Indications